Showing results (1301-1310 of 2,171) with videos related to
Sort By:
Pageof 218
Frontiers in Immunology|November 9, 2018
CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue SyndromeFane F K Mensah, Christopher W Armstrong, Venkat Reddy, et al.American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.Journal of Chromatography. A|March 18, 2014
Isopropyl derivative of cyclofructan 6 as chiral selector in liquid chromatography and capillary electrophoresisVítězslav Maier, Květa Kalíková, Adam Přibylka, et al.Dermatology and Therapy|July 30, 2024
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic DermatitisApril W Armstrong, H Chih-Ho Hong, Brian M Calimlim, et al.Ophthalmology|July 3, 2024
Visual Outcomes and Risk of Endophthalmitis in Open Globe Injuries without Intraocular Foreign Bodies with Delayed RepairMarisa G Tieger, Nakul Singh, Racquel Bitar, et al.Clinical Therapeutics|December 5, 2024
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized StudyAmita Datta-Mannan, Brian Moser, Wen Xu, et al.American Journal of Clinical Dermatology|October 26, 2021
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, April W Armstrong, et al.Ophthalmic Surgery, Lasers & Imaging Retina|October 19, 2023
Open Globe Injuries From Garage Door SpringsPriya P Shah, Romy Bejjani, Panisa Singhanetr, et al.Journal of the American Academy of Dermatology|October 22, 2023
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose studyKaren A Veverka, Steven T G Thng, Jonathan I Silverberg, et al.Plos One|January 26, 2019
Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitisApril W Armstrong, Ahong Huang, Li Wang, et al.Pageof 218